Nordea Investment Management AB Raises Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)

Nordea Investment Management AB boosted its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 22.5% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 282,834 shares of the company's stock after acquiring an additional 52,031 shares during the quarter. Nordea Investment Management AB's holdings in Roivant Sciences were worth $3,306,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of ROIV. Mutual of America Capital Management LLC increased its holdings in shares of Roivant Sciences by 0.4% in the 2nd quarter. Mutual of America Capital Management LLC now owns 327,079 shares of the company's stock valued at $3,457,000 after purchasing an additional 1,142 shares in the last quarter. GAMMA Investing LLC increased its holdings in Roivant Sciences by 57.0% in the fourth quarter. GAMMA Investing LLC now owns 3,548 shares of the company's stock valued at $42,000 after buying an additional 1,288 shares in the last quarter. Acadian Asset Management LLC increased its holdings in Roivant Sciences by 23.2% in the second quarter. Acadian Asset Management LLC now owns 8,510 shares of the company's stock valued at $89,000 after buying an additional 1,603 shares in the last quarter. Covestor Ltd lifted its position in shares of Roivant Sciences by 9.1% during the 3rd quarter. Covestor Ltd now owns 19,190 shares of the company's stock valued at $222,000 after acquiring an additional 1,605 shares during the period. Finally, US Bancorp DE boosted its stake in shares of Roivant Sciences by 146.5% during the 3rd quarter. US Bancorp DE now owns 3,278 shares of the company's stock worth $38,000 after acquiring an additional 1,948 shares in the last quarter. Institutional investors and hedge funds own 64.76% of the company's stock.

Insider Activity

In other news, COO Eric Venker sold 100,000 shares of Roivant Sciences stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $11.32, for a total value of $1,132,000.00. Following the completion of the sale, the chief operating officer now owns 606,525 shares of the company's stock, valued at $6,865,863. The trade was a 14.15 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CIO Mayukh Sukhatme sold 689,495 shares of the stock in a transaction dated Thursday, December 26th. The stock was sold at an average price of $12.01, for a total value of $8,280,834.95. Following the transaction, the executive now owns 18,836,547 shares in the company, valued at $226,226,929.47. This trade represents a 3.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,942,629 shares of company stock valued at $23,071,486 over the last 90 days. Insiders own 7.90% of the company's stock.

Roivant Sciences Stock Performance

ROIV stock traded down $0.39 during trading on Friday, hitting $10.63. The stock had a trading volume of 6,711,499 shares, compared to its average volume of 4,889,600. The stock has a market cap of $7.74 billion, a price-to-earnings ratio of 1.88 and a beta of 1.27. The company's 50 day moving average price is $11.86 and its two-hundred day moving average price is $11.57. Roivant Sciences Ltd. has a 1-year low of $9.69 and a 1-year high of $13.06.

Analyst Ratings Changes

Several brokerages recently issued reports on ROIV. HC Wainwright reaffirmed a "buy" rating and set a $18.00 price objective on shares of Roivant Sciences in a report on Wednesday, November 13th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Roivant Sciences in a research note on Thursday, September 19th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, Roivant Sciences presently has an average rating of "Moderate Buy" and an average target price of $17.93.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.